Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome Conditioning for ASCT in Lymphoma
NCT05681403Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label trial of mitoxantrone in non-Hodgkin lymphoma (NHL), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Recurrence rate at 36 months. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05681403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681403.